Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39 results about "Muscarinic M1 Receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.
Muscarinic M1 receptor agonists for pain management
InactiveUS20050130961A1Alleviate acute painRelieve symptomsBiocideNervous disorderAgonistNeuropathic pain
Disclosed herein are compounds and methods for treating chronic neuropathic pain. It has been discovered that compounds that selectively interact with a muscarinic receptor subtype are effective in treating neuropathic pain. Specifically, compounds that selectively interact with the M1 muscarinic receptor subtype may be used.
Owner:ACADIA PHARMA INC
Treatment of psychosis with a muscarinic m1 receptor ectopic activator
A muscarinic M1 receptor ectopic activator, such as a muscarinic M1 receptor allosteric potentiator or a muscarinic M1 receptor ectopic agonist is useful, alone or in combination with other antipsychotic agents, for treating or preventing psychosis, such as a schizophrenic disorder or psychosis in Alzheimer's disease or bipolar disorder, for enhancing cognition and for neuropathic pain.
Owner:MERCK & CO INC
Bicyclic AZA compounds as muscarinic M1 receptor agonists
ActiveUS9266857B2Organic active ingredientsIsotope introduction to heterocyclic compoundsM1 muscarinic receptorAgonist
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5, X1, X2 and p are as defined herein.
Owner:HEPTARES THERAPEUTICS
Compounds with activity on muscarinic receptors
Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
Owner:BRANN MARK +6
Muscarinic M1 receptor agonists
Owner:HEPTARES THERAPEUTICS
Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
ActiveUS10196380B2Similar effectHigh selectivityOrganic active ingredientsNervous disorderNitrogenM1 muscarinic receptor
This invention relates to compounds that are agonists of the muscarinic M1 receptor and / or M4 receptor and which are useful in the treatment of muscarinic M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
InactiveUS20160016907A1Improve sleep qualityImproving sleep maintenanceBiocideNervous disorderNegative symptomAllosteric modulator
The present invention provides, in part, compounds of Formula I:N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Owner:PFIZER INC
Bicyclic aza compounds as muscarinic m1 receptor agonists
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5, X1, X2 and p are as defined herein.
Owner:HEPTARES THERAPEUTICS
Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
Owner:HEPTARES THERAPEUTICS
Treating obesity with muscarinic receptor m1 antagonists
Owner:THERAKOS INC
Treating obesity with muscarinic receptor m1 antagonists
Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
Owner:THERAKOS INC
Substituted cyclohexanes as muscarinic m1 receptor and/or m4 receptor agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formulawherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
Owner:HEPTARES THERAPEUTICS
Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.(Formula I) (I)
Owner:SUVEN LIFE SCI LTD
Muscarinic m1 receptor positive allosteric modulators
ActiveUS20180155302A1Increase cerebral blood flowOrganic active ingredientsNervous disorderAllosteric modulatorMuscarinic M1 Receptors
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
Owner:SUVEN LIFE SCI LTD
Compound with activity on muscarinic receptors
Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
Owner:ACADIA PHARMA INC
Muscarinic m1 receptor agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor
ActiveUS20180072727A1High selectivityIncrease heightNervous disorderIsotope introduction to heterocyclic compoundsAgonistTreatment use
This invention relates to compounds that are agonists of the muscarinic M1 and / or M4 receptor and which are useful in the treatment of muscarinic M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula. (I) where p, q, r, s, X, Z, Y, R1, R2, R3 and R4 are as defined herein.
Owner:HEPTARES THERAPEUTICS
Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).
Owner:SUVEN LIFE SCI LTD
Fluoroindole Derivatives as Muscarinic M1 Receptor Positive Allosteric Modulators
ActiveUS20180244655A1Increase cerebral blood flowOrganic active ingredientsNervous disorderAllosteric modulatorMuscarinic M1 Receptors
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor. (Formula I) (I)
Owner:SUVEN LIFE SCI LTD
Muscarinic m1 receptor positive allosteric modulators
Owner:SUVEN LIFE SCI LTD
Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).
Owner:SUVEN LIFE SCI LTD
1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases
ActiveUS20190256478A1High activityGood pharmacological propertiesNervous disorderOrganic chemistryBenzodiazepineBenzene
The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
Owner:F HOFFMANN LA ROCHE & CO AG
Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
PendingCN113166160AOrganic active ingredientsNervous disorderAllosteric modulatorPharmaceutical Substances
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of such compounds.
Owner:SUVEN LIFE SCI LTD
Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators
ActiveUS10294217B2Increase cerebral blood flowOrganic active ingredientsNervous disorderAllosteric modulatorMuscarinic M1 Receptors
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor. (Formula I)(I)
Owner:SUVEN LIFE SCI LTD
Substituted cyclohexanes as muscarinic m1 receptor and/or m4 receptor agonists
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1 / M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formulawherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
Owner:HEPTARES THERAPEUTICS
Muscarinic M1 receptor positive allosteric modulators
ActiveUS10308620B2Increase cerebral blood flowOrganic active ingredientsNervous disorderAllosteric modulatorMuscarinic M1 Receptors
Owner:SUVEN LIFE SCI LTD
Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in treatment of CNS diseases and pains
Owner:HEPTARES THERAPEUTICS
Polycyclic amides as muscarinic M1 receptor positive allosteric modulators
Owner:SUVEN LIFE SCI LTD
Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I)
Owner:SUVEN LIFE SCI LTD
Muscarinic M1 receptor positive allosteric modulators
Owner:SUVEN LIFE SCI LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com